• Archer has built an alpha prototype Biosensor medical device achieving clinical-grade potassium sensing accuracy
• A beta prototype Biosensor suitable for preclinical validation is now under development
• The beta prototype is being designed as a robust, user-ready, and manufacturable system for future clinical trials and commercial deployment

Archer Materials Limited (ASX: AXE), a quantum technology company, has provided an update on the progress toward the development of its Biosensor beta prototype for blood potassium sensing and expansion into other diagnostic applications. Following the successful completion and demonstration of Archer's integrated alpha prototype, which achieved clinical-grade potassium sensing accuracy, the Company has advanced to the next stage of product development through the construction of its beta prototype Biosensor platform. The beta prototype program represents an important step toward external validation, future clinical studies, and commercial partnership development. Archer plans to develop multiple versions of the beta prototype with ongoing refinements informed by external testing, studies, and validation activities. The first beta prototype system is expected to become available for testing in the coming months, with additional optimization and validation planned throughout the second half of 2026, with the target of a fully optimized beta prototype for use in trials in 2027. The beta prototype Biosensor is being developed as a robust, user-ready, and manufacturable system designed to support future clinical workflows and commercial deployment pathways. Key progress includes the completion of the first beta prototype cartridge design, advancement of the handheld readout electronics and control system, commencement of further productization activities with IMEC, and engagement with contract development and manufacturing organizations to support future scale-up, manufacturing pathways, and clinical deployment activities. In parallel with potassium sensing development, Archer is also leveraging the Biochip platform to evaluate additional diagnostic applications, such as early feasibility testing for monitoring lithium levels in blood, targeting potential applications in the management of bipolar and other mood disorders.

The ongoing progress of the beta prototype Biosensor further de-risks the Biochip technology and positions Archer to generate external validation data in future development phases. These activities are expected to support engagement with Medtech partners, clinical collaborators, and manufacturing groups as Archer advances toward potential commercialization opportunities.